Steven Le Gouill, MD, PhD
Younger patients with mantle cell lymphoma lived significantly longer and without disease progression or clinical events when they received rituximab maintenance therapy after stem cell transplantation, final results of a randomized trial showed.
The primary endpoint was EFS, as determined from the time of randomization. Secondary endpoints included PFS and OS.
A review of baseline characteristics showed that the patients had a median age of 57, and that men accounted for 79% of the study population. By the Mantle Cell Lymphoma International Prognostic Index criteria, 53% of the patients had low-risk disease, 27.4% had intermediate-risk disease, and 19.5% had high-risk disease.
... to read the full story